These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 35083493)

  • 1. Treatment of Atopic Dermatitis with Baricitinib: First Real-life Experience.
    Rogner D; Biedermann T; Lauffer F
    Acta Derm Venereol; 2022 Mar; 102():adv00677. PubMed ID: 35083493
    [No Abstract]   [Full Text] [Related]  

  • 2. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
    JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world effectiveness and safety of baricitinib in Japanese patients with atopic dermatitis: A single-center retrospective study.
    Uchiyama A; Fujiwara C; Inoue Y; Motegi SI
    J Dermatol; 2022 Apr; 49(4):469-471. PubMed ID: 35253254
    [No Abstract]   [Full Text] [Related]  

  • 5. Baricitinib in patients with moderate-to-severe atopic dermatitis: Results from a randomized monotherapy phase 3 trial in the United States and Canada (BREEZE-AD5).
    Simpson EL; Forman S; Silverberg JI; Zirwas M; Maverakis E; Han G; Guttman-Yassky E; Marnell D; Bissonnette R; Waibel J; Nunes FP; DeLozier AM; Angle R; Gamalo M; Holzwarth K; Goldblum O; Zhong J; Janes J; Papp K
    J Am Acad Dermatol; 2021 Jul; 85(1):62-70. PubMed ID: 33600915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Case report: Baricitinib combined with adjuvant therapy for treatment of atopic dermatitis in a child.
    Chen JC; Lian CH
    Dermatol Ther; 2021 Mar; 34(2):e14818. PubMed ID: 33506529
    [No Abstract]   [Full Text] [Related]  

  • 7. Disseminated tinea corporis under baricitinib therapy for atopic dermatitis.
    Fiocco Z; Kerl K; French LE; Reinholz M; Dietrich C
    Dermatol Ther; 2022 Apr; 35(4):e15351. PubMed ID: 35103361
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of baricitinib add-on therapy in atopic dermatitis patients treated with dupilumab.
    Kook HD; Hong N; Lee DH; Jung HJ; Park MY; Ahn J
    Dermatol Ther; 2022 Jul; 35(7):e15525. PubMed ID: 35441774
    [No Abstract]   [Full Text] [Related]  

  • 9. Effectiveness of baricitinib in prurigo-type atopic dermatitis: A case report.
    He Y; Ji S; Yu Q
    Dermatol Ther; 2021 Mar; 34(2):e14878. PubMed ID: 33583117
    [No Abstract]   [Full Text] [Related]  

  • 10. Refractory cutaneous lichen amyloidosis coexisting with atopic dermatitis responds to the Janus Kinase inhibitor baricitinib.
    Xia D; Xiao Y; Li M; Li W
    Dermatol Ther; 2022 Sep; 35(9):e15724. PubMed ID: 35855568
    [No Abstract]   [Full Text] [Related]  

  • 11. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of baricitinib in combination with topical corticosteroids in patients with moderate-to-severe atopic dermatitis with inadequate response, intolerance or contraindication to ciclosporin: results from a randomized, placebo-controlled, phase III clinical trial (BREEZE-AD4).
    Bieber T; Reich K; Paul C; Tsunemi Y; Augustin M; Lacour JP; Ghislain PD; Dutronc Y; Liao R; Yang FE; Brinker D; DeLozier AM; Meskimen E; Janes JM; Eyerich K;
    Br J Dermatol; 2022 Sep; 187(3):338-352. PubMed ID: 35484697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible suppressive effects of baricitinib on serum IL-22 levels in atopic dermatitis.
    Uchiyama A; Fujiwara C; Inoue Y; Ishikawa M; Motegi SI
    J Dermatol Sci; 2022 Jun; 106(3):189-192. PubMed ID: 35459598
    [No Abstract]   [Full Text] [Related]  

  • 14. Improvement in symptoms of anxiety and depression in patients with atopic dermatitis after treatment with baricitinib.
    Thyssen JP; Lio P; Ball S; Pierce E; Sun L; Chen Y; Tan JKL; Augustin M
    J Eur Acad Dermatol Venereol; 2022 Feb; 36(2):e147-e150. PubMed ID: 34553429
    [No Abstract]   [Full Text] [Related]  

  • 15. Onset of Symptom Relief Reported in Daily Diaries of Patients With Atopic Dermatitis Treated With Baricitinib in a United States Clinical Trial (BREEZE-AD5).
    Rosmarin D; Casillas M; Chen S; Dawson Z; Pierce E; Zhang H; Bukhalo M; Smith S
    J Cutan Med Surg; 2022; 26(3):262-266. PubMed ID: 35086348
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid Improvement in Skin Pain Severity and Its Impact on Quality of Life in Adult Patients With Moderate-to-Severe Atopic Dermatitis From a Double-Blind, Placebo-Controlled Baricitinib Phase 3 Study.
    Rosmarin D; Fretzin S; Strowd L; Casillas M; DeLozier AM; Dawson Z; Chen S; Lu N; Thyssen JP
    J Cutan Med Surg; 2022; 26(4):377-385. PubMed ID: 35354410
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Journal club: New small molecules for atopic dermatitis management.
    Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E
    Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077
    [No Abstract]   [Full Text] [Related]  

  • 18. Dupilumab-induced enthesoarthritis and refractory atopic dermatitis successfully treated with baricitinib.
    De Stefano L; Bobbio-Pallavicini F; Montecucco C; Bugatti S
    Rheumatology (Oxford); 2022 Mar; 61(3):e64-e66. PubMed ID: 34647989
    [No Abstract]   [Full Text] [Related]  

  • 19. Baricitinib improved alopecia areata concomitant with atopic dermatitis: A case report.
    Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
    J Dermatol; 2021 Sep; 48(9):e472-e473. PubMed ID: 34151450
    [No Abstract]   [Full Text] [Related]  

  • 20. Impact of baricitinib in combination with topical steroids on atopic dermatitis symptoms, quality of life and functioning in adult patients with moderate-to-severe atopic dermatitis from the BREEZE-AD7 Phase 3 randomized trial.
    Wollenberg A; Nakahara T; Maari C; Peris K; Lio P; Augustin M; Silverberg JI; Rueda MJ; DeLozier AM; Pierce E; Yang FE; Sun L; Ball S; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2021 Jul; 35(7):1543-1552. PubMed ID: 33834521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.